Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from CG Oncology, Inc. ( (CGON) ).
On January 9, 2026, CG Oncology announced that topline data from its Phase 3 PIVOT-006 trial of adjuvant intravesical cretostimogene grenadenorepvec in intermediate-risk non-muscle invasive bladder cancer are now expected in the first half of 2026, nearly a year earlier than originally planned, following rapid enrollment of more than 360 patients across over 90 sites. The company highlighted that PIVOT-006 is the first randomized Phase 3 registrational study in this underserved patient group, which is estimated to exceed 50,000 individuals in the U.S., and the accelerated timeline, alongside encouraging safety and efficacy signals from the BOND-003 and CORE-008 studies reported as of September 1, 2025, underscores cretostimogene’s potential to reshape the treatment landscape for NMIBC and could materially strengthen CG Oncology’s position in bladder cancer therapeutics if future results remain favorable.
The most recent analyst rating on (CGON) stock is a Buy with a $89.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.
Spark’s Take on CGON Stock
According to Spark, TipRanks’ AI Analyst, CGON is a Neutral.
CG Oncology, Inc. shows potential due to promising clinical trial results and a strong equity base. However, financial challenges, including no revenue and reliance on external funding, weigh heavily on the score. The positive technical indicators and strategic positioning in a lucrative market provide some optimism.
To see Spark’s full report on CGON stock, click here.
More about CG Oncology, Inc.
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies for patients with non-muscle invasive bladder cancer (NMIBC). Its lead investigational product, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy being evaluated across a broad clinical program that includes two Phase 3 trials in high-risk BCG-unresponsive and intermediate-risk NMIBC, a Phase 2 study in high-risk BCG-naïve disease, and an expanded access program in North America.
Average Trading Volume: 891,105
Technical Sentiment Signal: Buy
Current Market Cap: $3.42B
Find detailed analytics on CGON stock on TipRanks’ Stock Analysis page.